ECOG PS: The Eastern Cooperative Oncology Group Performance KPS: Karnofsky Performance Status Scale HRQoL: Health-related quality of life QoL: Quality of life MIS: Minimally invasive surgery NCCN: National Comprehensive Cancer Network HPV: Human papilloma virus PCP: Primary care provider ...
人表皮生长因子受体2(HER2)的过表达是胃癌预后差的指标。在国际ToGA试验(Trastuzumab with chemotherapy in HER2-positive advanced gastric cancer, 曲妥珠单抗与化疗治疗HER2阳性晚期胃癌),约22%的晚期胃癌患者的肿瘤中有HER2过表达。在这个III期临床试验中,594例HER2阳性晚期胃癌患者随机化接受单纯的标准化疗或化疗加曲...
5. 二代测序(next-generation sequencing,NGS):NGS可评估胃癌的遗传改变,从而指导胃癌的精准治疗。在晚期胃癌中使用NGS被NCCN指南列为2A类建议,用于确定治疗方案和(或)临床试验入组参考,特别对于药物治疗无效或病理组织取材有限的病例,考虑行NGS指导治疗,也用于MSI、TMB及ctDNA检测。 预防对策: 1、养成良好的饮食习惯...
胃远端肿瘤的胃次全切除术淋巴结清扫术:关于淋巴结清扫的范围有争议;美国国家综合癌症网络(national comprehensive cancer network, NCCN)建议D2清扫优于D1清扫;一个保留胰和脾的D2清扫提供的分期信息更多,且尽可能避免过度损伤时可能有利于生存 [4]化疗用于管理胃癌的抗肿瘤药物及药物联合包括如下:...
in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023 Jun 14:S1470-2045(23)00215-...
NCCN: National Comprehensive Cancer Network CR: Complete response PR: Partial response irAEs: Immune-related adverse events IBP: Immunotherapy beyond progression PD: Progression disease AJCC: American Joint Committee on Cancer ECOG PS: Eastern Cooperative Oncology Group performance status EMRs...
Gastric Cancer, Version 2.2022Jaffer A. Ajani, MD 1,* ; Thomas A. D’Amico, MD 2,* ; David J. Bentrem, MD, MS 3 ; Joseph Chao, MD 4 ; David Cooke, MD 5,* ;Carlos Corvera, MD 6 ; Prajnan Das, MD, MS, MPH 1,* ; Peter C. Enzinger, MD 7 ; Thomas Enzler, MD, PhD...
12.Wang F, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.Cancer Commun (Lond). 2024 Jan;44(1):127-172. 参考资料: 1.阿斯利康中国官微 精彩直播预告 ...
HER2 testing in gastric cancer: an update. World J. Gastroenterol. 22, 4619–4625 (2016). Article CAS PubMed PubMed Central Google Scholar Ajani, J. A. et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 20, 167–192 (...
Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial. 2023 ESMO Asia...